Back to Single Peptide Protocols
Single PeptideMetabolic & Weight Loss20 mg vialWeeklySubcutaneousGLP-1/GIP/Glucagon
Retatrutide (20 mg Vial) Dosage Protocol
Full dosage protocol for the triple-agonist GLP-1/GIP/glucagon receptor peptide in a 20 mg vial. Includes titration schedule.
Vial Size
20 mg
Route
Subcutaneous
Frequency
Once weekly
Dose Range
2–12 mg/week
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–4 | 2 mg |
| Weeks 5–8 | 4 mg |
| Weeks 9–12 | 8 mg |
| Weeks 13+ | 12 mg |
Route: Subcutaneous · Frequency: Once weekly · Cycle: 24–52 weeks
How It Works
Retatrutide is a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed 24.2% body weight reduction at 48 weeks — the highest reported for any weekly injectable.
Potential Benefits
- •Phase 2: 24.2% mean weight loss at 48 weeks (highest of any weekly injectable).
- •Triple mechanism: appetite suppression + energy expenditure + fat oxidation.
- •Significant improvement in metabolic markers.
Side Effects & Risks
- •Nausea, vomiting, diarrhea (dose-dependent).
- •Currently in Phase 3 trials; not yet FDA-approved.
Important Notes
- Investigational compound — not FDA-approved.
- Titrate slowly to minimize GI side effects.
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 28 days.
References
- [1]Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.